iECURE has licensed the ARCUS® nuclease from Precision BioSciences for four gene insertion programs including OTC, CTLN1 and PKU.

The poster presentation at SIMD will feature one-year post-treatment data from the first infant dosed in the study who achieved a complete clinical response as defined by study protocol, including sustained discontinuation of standard-of-care therapies.

American Society of Gene & Cell Therapy Annual Meeting:

Oral Presentation: Decreased rate of hyperammonemic crises in infants with neonatal-onset OTC deficiency post ECUR-506 administration: preliminary update from the OTC-HOPE study

  • Session: Clinical Trials: In vivo gene transfer and gene-editing therapies
  • Date/Time: Wednesday, May 13, 4:00 p.m. – 4:15 p.m. ET
  • Location: MCEC Room 210ABC (Level 2)
  • Presenter: Gabriel Cohn, M.D., MBA, Chief Medical Officer

Society for Inherited Metabolic Disorders Meeting:

Poster Presentation: Sustained Clinical Response in First Clinical TrialPatient Dosed with ECUR-506 One Year Post Discontinuation of Standard of Care (#037)

  • Session: Poster Session
  • Date/Time: Monday, May 18, 8:00 p.m. – 9:00 p.m. ET
  • Location: Rio Mar Ballroom Foyer
  • Presenter: George Diaz, M.D., Ph.D., VP, Therapeutic Area Lead, UCDs

iECURE will also be presenting an exhibitor booth at SIMD, May 18-19, 2026, at the Rio Mar Ballroom Foyer in the Wyndham Rio Mar Beach Resort, Booth #6.